AbbVie, Inc. (ABBV)
262.82
+2.89
(+1.11%)
USD |
NYSE |
Oct 02, 16:00
263.85
+1.03
(+0.39%)
After-Hours: 20:00
AbbVie Enterprise Value : 528.72B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 528.72B |
| October 01, 2026 | 523.61B |
| September 30, 2026 | 526.55B |
| September 29, 2026 | 529.55B |
| September 28, 2026 | 534.84B |
| September 25, 2026 | 531.41B |
| September 24, 2026 | 532.79B |
| September 23, 2026 | 532.71B |
| September 22, 2026 | 532.94B |
| September 21, 2026 | 531.65B |
| September 18, 2026 | 530.74B |
| September 17, 2026 | 530.84B |
| September 16, 2026 | 528.17B |
| September 15, 2026 | 529.11B |
| September 14, 2026 | 526.87B |
| September 11, 2026 | 518.65B |
| September 10, 2026 | 514.90B |
| September 09, 2026 | 507.68B |
| September 08, 2026 | 503.91B |
| September 04, 2026 | 517.48B |
| September 03, 2026 | 524.11B |
| September 02, 2026 | 526.78B |
| September 01, 2026 | 523.72B |
| August 31, 2026 | 517.41B |
| August 28, 2026 | 515.75B |
| Date | Value |
|---|---|
| August 27, 2026 | 520.47B |
| August 26, 2026 | 528.86B |
| August 25, 2026 | 533.97B |
| August 24, 2026 | 531.73B |
| August 21, 2026 | 532.50B |
| August 20, 2026 | 526.97B |
| August 19, 2026 | 534.29B |
| August 18, 2026 | 521.83B |
| August 17, 2026 | 506.65B |
| August 14, 2026 | 505.11B |
| August 13, 2026 | 507.52B |
| August 12, 2026 | 503.88B |
| August 11, 2026 | 506.23B |
| August 10, 2026 | 502.48B |
| August 07, 2026 | 499.07B |
| August 06, 2026 | 495.24B |
| August 05, 2026 | 499.35B |
| August 04, 2026 | 495.11B |
| August 03, 2026 | 497.41B |
| July 31, 2026 | 507.73B |
| July 30, 2026 | 519.16B |
| July 29, 2026 | 529.57B |
| July 28, 2026 | 529.39B |
| July 27, 2026 | 518.28B |
| July 24, 2026 | 522.61B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Biogen, Inc. | 39.55B |
| Gilead Sciences, Inc. | 200.90B |
| Amgen, Inc. | 261.20B |
| Regeneron Pharmaceuticals, Inc. | 70.72B |
| Johnson & Johnson | 644.86B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.604B |
| Revenue (Quarterly) | 16.99B |
| Total Expenses (Quarterly) | 13.39B |
| EPS Diluted (Quarterly) | 2.033 |
| Gross Profit Margin (Quarterly) | 74.71% |
| Profit Margin (Quarterly) | 21.21% |
| Earnings Yield | 1.35% |
| Operating Earnings Yield | 4.72% |
| Normalized Earnings Yield | 3.064 |